Weight loss on tirzepatide roughly doubles without diabetes

Tirzepatide is prescribed both to people with type 2 diabetes and to people with overweight or obesity who do not have diabetes, and it is reasonable to ask whether it works equally well in both groups. If the drug's effect on weight differs meaningfully by diabetes status, that shapes what different users can realistically expect from treatment. Previous trials enrolled these populations separately, so a pooled analysis that stratifies cleanly by diabetes status can quantify the gap with more precision than any single trial. That is what this review set out to do, for both efficacy and safety.

The authors systematically searched MEDLINE, Embase and the Cochrane Library for randomised controlled trials comparing once-weekly tirzepatide at doses of 5 to 15 mg with placebo, in adults with or without diabetes, lasting at least 26 weeks. Five trials (n=2,174) enrolled patients with diabetes and a BMI of at least 23 kg/m2, and five trials (n=4,467) enrolled patients without diabetes and a BMI of at least 27 kg/m2 (at least 24 in Asia). Random-effects models pooled risk ratios for dichotomous endpoints and mean differences for continuous ones, analysed separately by diabetes status.

Tirzepatide produced significantly greater weight loss than placebo in both groups, but the effect was roughly twice as large without diabetes: an absolute reduction of 18.11 kg and a relative reduction of 17.15%, versus 9.06 kg and 9.54% in those with diabetes. In both subpopulations the drug significantly increased the probability of losing at least 5%, 10% and 15% of body weight, and improved BMI, waist circumference, blood pressure, haemoglobin A1c and lipid levels. The weight-related benefits were statistically significantly greater in the group without diabetes. Safety was similar across the two subpopulations, consisting predominantly of mild-to-moderate, well-tolerated adverse events.

This analysis confirms tirzepatide's substantial placebo-controlled weight effect and puts a clear number on something clinicians have observed across incretin-based drugs: people with diabetes tend to lose less weight on them. The abstract does not explain why the gap exists, so the mechanism remains an open question. It is also worth noting the two populations came from different trials with different BMI entry criteria rather than being randomised against each other, so the comparison is across trial programmes rather than within one. The senior author declares extensive ties to manufacturers including Eli Lilly, which makes tirzepatide.

If you have wondered why headline weight-loss figures for these drugs sometimes look very different between studies, diabetes status is a large part of the answer: the same drug produced roughly double the average loss in trial participants without diabetes. That is useful context for interpreting claims about what tirzepatide achieves: the population studied matters enormously. This is information about how trial results should be read, not guidance on treatment, which sits with a prescriber.